DCOY
Decoy Therapeutics Inc.
Key Financials
Net Income
$-12518480
↓ 124.5%
EPS (Diluted)
$-129.10
↓ 2129.7%
Operating Income
$-12613952
↓ 120.0%
Revenue
$0
↓ 100.0%
Total Liabilities
$5.2M
↑ 241.9%
Total Assets
$11.1M
↑ 265.8%
Shareholders' Equity
$5.9M
↑ 289.6%
Operating Cash Flow
$-4827188.00
↓ 6.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEF 14A | 8/4/2026 | View on SEC |
| DEFA14A | 8/4/2026 | View on SEC |
| 3 | 7/31/2026 | View on SEC |
| PRE 14A | 7/24/2026 | View on SEC |
| EFFECT | 7/17/2026 | View on SEC |
| 424B3 | 7/17/2026 | View on SEC |
| 8-K | 7/15/2026 | View on SEC |
| S-1 | 7/10/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| EFFECT | 6/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DCOY |
| Company Name | Decoy Therapeutics Inc. |
| CIK | 1615219 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 346-772-0346 |